Literature DB >> 3537195

The pore-forming protein (perforin) of cytolytic T lymphocytes is immunologically related to the components of membrane attack complex of complement through cysteine-rich domains.

J D Young, C C Liu, L G Leong, Z A Cohn.   

Abstract

Structural, functional and immunological similarities between the ninth component of complement (C9) and the lymphocyte pore-forming protein (PFP, perforin) have recently been described (8-10). PFP is shown here to be immunologically related to all other components of the membrane attack complex (MAC) of human complement, namely, C5b-6, C7, C8, and C9. Polyclonal antibodies raised against purified human C5b-6, C7, C8, or C9 react with other components of the MAC and with mouse lymphocyte PFP. The antigenic epitopes shared by human complement proteins and mouse lymphocyte PFP are limited to cysteine-rich domains. Only complement proteins that have been reduced and alkylated elicit the production of crossreactive antibodies when used as immunogens. The nonreduced forms of complement components or lymphocyte PFP neither react with these antibodies nor give rise to crossreactive antibodies. The homologous domains of complement proteins and lymphocyte PFP may play related functions in their attachment to lipid membranes and assembly of membrane lesions.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3537195      PMCID: PMC2188482          DOI: 10.1084/jem.164.6.2077

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  24 in total

Review 1.  Complement.

Authors:  H J Müller-Eberhard
Journal:  Annu Rev Biochem       Date:  1975       Impact factor: 23.643

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 3.  Mechanism of lymphocyte-mediated cytotoxicity.

Authors:  P A Henkart
Journal:  Annu Rev Immunol       Date:  1985       Impact factor: 28.527

4.  Neoantigen of the complement membrane attack complex of cytotoxic human peripheral blood lymphocytes.

Authors:  J S Sundsmo; H J Müller-Eberhard
Journal:  J Immunol       Date:  1979-06       Impact factor: 5.422

5.  Nucleotide sequence of cDNA and derived amino acid sequence of human complement component C9.

Authors:  R G DiScipio; M R Gehring; E R Podack; C C Kan; T E Hugli; G H Fey
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

6.  Monoclonal antibodies which react with lymphocyte-lysed target cells and which cross-react with complement-lysed ghosts.

Authors:  R H Ward; P J Lachmann
Journal:  Immunology       Date:  1985-09       Impact factor: 7.397

7.  Purification of the sixth and seventh component of human complement without loss of hemolytic activity.

Authors:  E R Podack; W P Kolb; H J Müller-Eberhard
Journal:  J Immunol       Date:  1976-02       Impact factor: 5.422

8.  Isolation and biochemical and functional characterization of perforin 1 from cytolytic T-cell granules.

Authors:  E R Podack; J D Young; Z A Cohn
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

9.  Identification and characterization of a pore-forming protein of human peripheral blood natural killer cells.

Authors:  C C Liu; B Perussia; Z A Cohn; J D Young
Journal:  J Exp Med       Date:  1986-12-01       Impact factor: 14.307

10.  The membrane attack mechanism of complement: the three polypeptide chain structure of the eigth component (C8).

Authors:  W P Klob; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1976-05-01       Impact factor: 14.307

View more
  12 in total

1.  In vivo expression of perforin by natural killer cells during a viral infection. Studies on uveitis produced by herpes simplex virus type I.

Authors:  L H Young; C S Foster; J D Young
Journal:  Am J Pathol       Date:  1990-05       Impact factor: 4.307

Review 2.  Susceptibility of human and murine drug-resistant tumor cells to the lytic activity of rIL2-activated lymphocytes (LAK).

Authors:  C Gambacorti-Passerini; L Rivoltini; M Radrizzani; R Supino; M Mariani; G Parmiani
Journal:  Cancer Metastasis Rev       Date:  1988-12       Impact factor: 9.264

3.  Macrophage damage by Leishmania amazonensis cytolysin: evidence of pore formation on cell membrane.

Authors:  F S Noronha; J S Cruz; P S Beirão; M F Horta
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

4.  Imaging of lytic granule exocytosis in CD8+ cytotoxic T lymphocytes reveals a modified form of full fusion.

Authors:  Jose A Martina; Xufeng S Wu; Marta Catalfamo; Takeshi Sakamoto; Chang Yi; John A Hammer
Journal:  Cell Immunol       Date:  2011-07-24       Impact factor: 4.868

5.  Molecular characterization of the alpha subunit of complement component C8 (GcC8alpha) in the nurse shark (Ginglymostoma cirratum).

Authors:  Lydia Aybar; Dong-Ho Shin; Sylvia L Smith
Journal:  Fish Shellfish Immunol       Date:  2009-06-12       Impact factor: 4.581

6.  Resistance of cytolytic lymphocytes to perforin-mediated killing. Lack of correlation with complement-associated homologous species restriction.

Authors:  S B Jiang; P M Persechini; A Zychlinsky; C C Liu; B Perussia; J D Young
Journal:  J Exp Med       Date:  1988-12-01       Impact factor: 14.307

7.  Serine esterase and hemolytic activity in human cloned cytotoxic T lymphocytes.

Authors:  W S Ferguson; C R Verret; E B Reilly; M J Iannini; H N Eisen
Journal:  J Exp Med       Date:  1988-02-01       Impact factor: 14.307

8.  Resistance of cloned cytotoxic T lymphocytes to cell-mediated cytotoxicity.

Authors:  A Blakely; K Gorman; H Ostergaard; K Svoboda; C C Liu; J D Young; W R Clark
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

9.  Inhibition of antibody-dependent lymphocyte cytotoxicity by homologous restriction factor incorporated into target cell membranes.

Authors:  L S Zalman; L M Wood; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

10.  Zanvil Alexander Cohn 1926-1993.

Authors:  R M Steinman; C L Moberg
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.